Articles tagged "Immunosuppression"

2015 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
C. Baum,¹ M. Khattar,² P. Schroder,¹ W. Chen,³ S. Stepkowski.¹
¹Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH; ²Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA; ³Transplant Immunology Research Program, Houston Methodist Research Institute, Houston, TX.
BACKGROUND: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system. This makes it an attractive target for reducing chronic allograft…
2015 American Transplant Congress
Not Only CD28null But Also CD28pos T Cells Contribute to Rejection During Belatacept Treatment
G. de Graav,¹ D. Hesselink,¹ R. Kraaijeveld,¹ M. Dieterich,¹ W. Weimar,¹ M. Clahsen-Van Groningen,² C. Baan.¹
¹Internal Medicine, Erasmus Medical Center, Rotterdam, South Holland, Netherlands; ²Pathology, Erasmus Medical Center, Rotterdam, South Holland, Netherlands.
To explain the underlying immunological mechanisms for rejection under belatacept treatment, the phenotypical and functional characteristics of graft infiltrating lymphocytes were studied during rejection under…
2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ D. Ghinolfi,¹ D. Campani,² F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…
2015 American Transplant Congress
Aging Enhances Immunosuppressives Capacities of Tacrolimus By Functional Changes of CD4+ T-Cells
F. Krenzien,¹ M. Quante,¹ A. ElKhal,¹ H. Uehara,¹ R. Abdi,² B. Slegtenhorst,¹ H. Biefer,¹ S. Tullius.¹
¹Transplant Surgery Research Laboratory and Division of Transplant Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Immunosenescence has broad consequences on alloimmunity and immunosuppression in the elderly may require age-adaptation. Here, we investigated the influence of aging on the effectivity of…
2015 American Transplant Congress
Customized Reminders and Provider Notification to Improve Adherence to Immunosuppression
P. Reese, R. Bloom, J. Trofe-Clark, A. Mussell, D. Leidy, S. Levsky, J. Zhu, Y. Lin, A. Troxel, H. Feldman, K. Volpp.
UPenn, Philadelphia, PA.
Background: Non-adherence to transplant immunosuppression is associated with an elevated risk of allograft loss. Novel, wireless-enabled pill bottles have created the opportunity to monitor patient…
2015 American Transplant Congress
Influence of POR*28 Genotype on Tacrolimus Disposition in Heart Transplant Recipients
T. Alford,¹ R. Page,¹ J. Lindenfeld,² C. Aquilante.¹
¹University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; ²University of Colorado School of Medicine, Aurora, CO.
Polymorphisms in P450 oxidoreductase (POR) have been shown to modulate CYP3A activity and alter the pharmacokinetics of CYP3A substrates, such as tacrolimus (TAC). The objective…
2015 American Transplant Congress
Induction Therapy With either Anti-Thymocyte Antibodies or Il2 Receptor Inhibitors Appears to Decrease the Risk of Graft Loss in DCD Liver Transplantation Compared to No Induction Therapy
S. Rayhill, J. Haldorson, A. Dick, S. Nazarian, L. Sibulesky, M. Montenovo, L. Yu, I. Javid, T. Pearson, R. Bakthavatsalam, P. Healey, J. Perkins, J. Reyes.
University of Washington, Seattle.
An analysis of our center's outcomes in DCD liver transplants suggested that induction with anti-thymocyte antibody preparations (ATG) may reduce the risk of graft loss…
2015 American Transplant Congress
Inhibition of T Cell Metabolism Reveals a New Approach to Preventing Graft Rejection
C.-F. Lee,^1,2 Y.-C. Lo,² G. Furtmüller,³ B. Oh,³ V. Andrade-Oliveira,² A. Thomas,⁴ G. Brandacher,³ J. Powell.²
¹Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital-Linkou Branch, Taoyuan, Taiwan; ²Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; ³Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ⁴Brain Science Institute, Neurotranslational Program Johns Hopkins University School of Medicine, Baltimore, ND.
Upon antigen recognition and co-stimulation, T cells up-regulate the metabolic machinery necessary to proliferate and sustain effector function. Hallmarks of this response include a switch…
2015 American Transplant Congress
Explorative Analysis of ZEUS After 5 Years: Histological Assessment from Biopsy Analyses
U. Eisenberger,¹ K. Budde,¹ O. Witzke,¹ F. Lehner,¹ C. Sommerer,¹ R. Wuethrich,³ P. Reinke,¹ A. Muehlfeld,¹ K. Heller,¹ R. Stahl,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,² W. Arns.¹
¹ZEUS Study Group, Germany; ²Novartis, Pharma, Germany; ³ZEUS Study Group, Switzerland.
Background: Analysis of pathologists' assessments and histological data allow for deeper insight on patient outcome together with investigator's final clinical diagnoses. Here we present 5…
2015 American Transplant Congress
Calcineurin Inhibitor-Free Immunossupresion After Kidney Transplantation, Using Everolimus De Novo – Single Center Experience
M. Stronka, Z. Adamska, L. Cichanska, J. Kubiak, M. Gamrat, M. Karczewski.
Department of Transplantology, General, Vascular and Plastic Surgery, Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland.
The aim of the study was to analyse the clinical outcome in kidney transplant recipients treated with CNI (calcineurin inhibitors)-free protocol versus kidney transplant recipients…